GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE

Authors

  • Abdiqodirova D.A. Author

Keywords:

•Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors, Dapagliflozin, Empagliflozin, Gender Differences, Adverse Effects, Urinary Tract Infections (UTIs), Diabetic Ketoacidosis (DKA), Pharmacokinetics, Personalized Medicine.

Abstract

    Type 2 diabetes mellitus (T2DM) remains a significant global health issue and a leading cause of chronic kidney disease (CKD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, have demonstrated protective effects on renal function. However, their adverse effects may differ based on patient characteristics, particularly gender. This study explores emerging research on gender disparities in the adverse effects of dapagliflozin and empagliflozin among patients with CKD and T2DM.     Understanding the impact of dapagliflozin and empagliflozin on male and female patients with CKD is crucial for optimizing treatment strategies. While both drugs have demonstrated significant benefits in renal protection and cardiovascular risk reduction, concerns regarding gender-specific adverse reactions, including urinarytract infections, ketoacidosis, and volume depletion, remain under investigation. This study aims to provide a comparative analysis of the adverse effects of dapagliflozin and empagliflozin in male and female patients with CKD associated to highlight gender-based variations and their implications for personalized treatment 
approaches. with T2DM. By reviewing clinical outcomes and recent research directions, we seek

References

1. Jabbour, S., Seufert, J., Scheen, A. J., Bailey, C. J., Karup, C., & Meininger, G.

(2018). Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of

safety data from clinical trials. Diabetes Therapy, 9(4), 1455-1469.

2. Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., Chertow, G. M., Greene,

T., Hou, F. F., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic

kidney disease. New England Journal of Medicine, 383(15), 1436-1446.

3. Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., &

Leiter, L. A. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

New England Journal of Medicine, 380(4), 347-357.

4. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan,

D. M., & Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2

diabetes and nephropathy. New England Journal of Medicine, 380(24), 229-2306.

5. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., &

Johansen, O. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in

type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.

6. Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher,

M., & Johansen, O. E. (2018). How does empagliflozin reduce cardiovascular

mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial.

Diabetes Care, 41(2)

Published

2025-03-26

How to Cite

GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE . (2025). Global Science Review, 2(1), 418-422. https://global-science-review.com/ojs/index.php/gsr/article/view/238